Skip to main content
Top
Published in: Trials 1/2022

Open Access 01-12-2022 | Methodology

Examining evidence of time-dependent treatment effects: an illustration using regression methods

Authors: Kim M. Jachno, Stephane Heritier, Robyn L. Woods, Suzanne Mahady, Andrew Chan, Andrew Tonkin, Anne Murray, John J. McNeil, Rory Wolfe

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

For the design and analysis of clinical trials with time-to-event outcomes, the Cox proportional hazards model and the logrank test have been the cornerstone methods for many decades. Increasingly, the key assumption of proportionality—or time-fixed effects—that underpins these methods has been called into question. The availability of novel therapies with new mechanisms of action and clinical trials of longer duration mean that non-proportional hazards are now more frequently encountered.

Methods

We compared several regression-based methods to model time-dependent treatment effects. For illustration purposes, we used selected endpoints from a large, community-based clinical trial of low dose daily aspirin in older persons. Relative and absolute estimands were defined, and analyses were conducted in all participants. Additional exploratory analyses were undertaken by selected subgroups of interest using interaction terms in the regression models.

Discussion

In the trial with median 4.7 years follow-up, we found evidence for non-proportionality and a time-dependent treatment effect of aspirin on cancer mortality not previously reported in trial findings. We also found some evidence of time-dependence to an aspirin by age interaction for major adverse cardiovascular events. For other endpoints, time-fixed treatment effect estimates were confirmed as appropriate.

Conclusions

The consideration of treatment effects using both absolute and relative estimands enhanced clinical insights into potential dynamic treatment effects. We recommend these analytical approaches as an adjunct to primary analyses to fully explore findings from clinical trials.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cox DR. Regression models and life-tables. J R Stat Soc Ser B Methodol. 1972;34(2):187–220. Cox DR. Regression models and life-tables. J R Stat Soc Ser B Methodol. 1972;34(2):187–220.
4.
go back to reference Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer. 1995;72(2):511–8.CrossRef Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer. 1995;72(2):511–8.CrossRef
11.
go back to reference Royston P, Lambert PC. Flexible parametric survival analysis using Stata: beyond the Cox model. College Station: Stata Press; 2011. Royston P, Lambert PC. Flexible parametric survival analysis using Stata: beyond the Cox model. College Station: Stata Press; 2011.
15.
go back to reference International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guidelines: Statistical Principles for Clinical Trials E9. London: European Medicines Agency; 1998. International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guidelines: Statistical Principles for Clinical Trials E9. London: European Medicines Agency; 1998.
16.
go back to reference ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Amsterdam: European Medicines Agency; 2020. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Amsterdam: European Medicines Agency; 2020.
18.
go back to reference Evaluation and reporting of age-. race-, and ethnicity-specific data in medical device clinical studies. Maryland: U.S. Food and Drug Administration; 2014. Evaluation and reporting of age-. race-, and ethnicity-specific data in medical device clinical studies. Maryland: U.S. Food and Drug Administration; 2014.
19.
go back to reference Evaluation and reporting of age-. race-, and ethnicity-specific data in medical device clinical studies. Maryland: U.S. Food and Drug Administration; 2017. Evaluation and reporting of age-. race-, and ethnicity-specific data in medical device clinical studies. Maryland: U.S. Food and Drug Administration; 2017.
50.
go back to reference Hernán MA, Robins J. Causal inference: what if. Boca Raton: Chapman and Hall/CRC; 2020. Hernán MA, Robins J. Causal inference: what if. Boca Raton: Chapman and Hall/CRC; 2020.
Metadata
Title
Examining evidence of time-dependent treatment effects: an illustration using regression methods
Authors
Kim M. Jachno
Stephane Heritier
Robyn L. Woods
Suzanne Mahady
Andrew Chan
Andrew Tonkin
Anne Murray
John J. McNeil
Rory Wolfe
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06803-x

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue